Warther Private Wealth LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.9% in the 3rd quarter, Holdings Channel reports. The fund owned 3,698 shares of the company’s stock after selling 500 shares during the quarter. Warther Private Wealth LLC’s holdings in AstraZeneca were worth $288,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter worth approximately $26,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca in the 1st quarter worth approximately $29,000. RFP Financial Group LLC increased its position in AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after buying an additional 178 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.
AstraZeneca Trading Down 0.2 %
AstraZeneca stock opened at $75.72 on Friday. The firm has a market capitalization of $234.78 billion, a price-to-earnings ratio of 36.67, a P/E/G ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a 50 day moving average of $80.59 and a 200 day moving average of $78.39. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.
Analyst Upgrades and Downgrades
AZN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. TD Cowen lifted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.
View Our Latest Research Report on AstraZeneca
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
- Five stocks we like better than AstraZeneca
- The Basics of Support and Resistance
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- EV Stocks and How to Profit from Them
- The Downtrend in UPS Stock Isn’t Over Yet
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.